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Molecular subtyping of Bacillus anthracis played an important role in differentiating and identifying strains
during the 2001 bioterrorism-associated outbreak. Because B. anthracis has a low level of genetic variabil-
ity, only a few subtyping methods, with varying reliability, exist. We initially used multiple-locus variable-
number tandem repeat analysis (MLVA) to subtype 135 B. anthracis isolates associated with the outbreak.
All isolates were determined to be of genotype 62, the same as the Ames strain used in laboratories. We
sequenced the protective antigen gene (pagA) from 42 representative outbreak isolates and determined
they all had a pagA sequence indistinguishable from the Ames strain (PA genotype I). MLVA and pagA
sequencing were also used on DNA from clinical specimens, making subtyping B. anthracis possible with-
out an isolate. Use of high-resolution molecular subtyping determined that all outbreak isolates were indis-
tinguishable by the methods used and probably originated from a single source. In addition, subtyping
rapidly identified laboratory contaminants and nonoutbreak–related isolates.
he recent bioterrorism-associated anthrax outbreak dem-
onstrated the need for rapid molecular subtyping of Bacil-
lus anthracis isolates. Numerous methods, including multiple-
locus enzyme electrophoresis (MEE) and multiple-locus
sequence typing (MLST), have shown the lack of genetic
diversity of B. anthracis (1–4, unpub. data). Despite this low
diversity, methods have been developed that can detect differ-
ences between B. anthracis isolates. Amplified fragment
length polymorphism (AFLP) analysis has been used to detect
differences between B. anthracis isolates and to examine phy-
logenetic relationships between B. anthracis and its close rela-
tives,  B. cereus and B. thuringiensis (4,5). Keim et al. (6)
reported on multiple-locus variable-number tandem repeat
analysis (MLVA) for subtyping B. anthracis, which unlike
AFLP is designed to subtype B. anthracis specifically and can-
not be used to address phylogenetic relationships between
Bacillus species. MLVA determines the copy number of vari-
able-number tandem repeats (VNTR) at eight genetic loci (six
chromosomal and one on each of the two plasmids). Recently,
MLVA has been used to differentiate 426 B. anthracis isolates
into 89 distinct genotypes and to study the ecology of anthrax
(6,7). MLVA is relatively simple, has excellent reproducibility,
can subtype multiple strains on a single gel, and gives results
in <8 hours.
Protective antigen (PA) is one of the three anthrax toxin
proteins and is key to developing immunity to anthrax.
Sequencing the gene that encodes PA (pagA) has been used to
subtype 26 diverse B. anthracis isolates into six PA genotypes
(8). Although sequencing of pagA results in limited numbers
of subtypes, it does have the added benefit of determining if
the pagA gene has been altered or engineered. 
During the 2001 bioterrorism-associated anthrax outbreak,
we used MLVA to subtype isolates from patients, the environ-
ment, and powders. Subtyping of B. anthracis allowed anthrax
cases to be linked to environmental specimens and powders
and provided information about potential sources. Sequencing
of pagA was also performed on a subset of these B. anthracis
isolates, and we confirmed that the pagA sequence was not
altered. In addition, we used these methods on DNA extracted
from select clinical specimens to detect and subtype B. anthra-
cis directly from clinical specimens. During the outbreak, lab-
oratories throughout the United States and around the world
received an increased number of specimens to be tested for B.
anthracis. With such large numbers, occasional contamination
or detection of non-outbreak strains was inevitable, and molec-
ular subtyping was used to clarify these situations on several
occasions. Overall, the recent anthrax outbreak has dramati-
cally illustrated the importance of rapid molecular subtyping
during a bioterrorism event.
Materials and Methods
During the 2001 anthrax outbreak investigation, 135 B.
anthracis isolates were subtyped. The identity of all strains
was confirmed with standard microbiologic procedures and
the Laboratory Response Network (LRN) testing algorithm
(9,10). Isolates were obtained from patients with laboratory- *Centers for Disease Control and Prevention, Atlanta, Georgia, USA
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confirmed anthrax (n=10), powders (n=4), and environmental
specimens (n=121). For comparison purposes, five B. anthra-
cis isolates originating from New England in the 1960s and
1970s, the Ames strain, and the Pasteur strain were included.
DNA extractions of 28 clinical specimens from six patients
with confirmed inhalational anthrax were used for molecular
subtyping. These specimens included blood, pleural fluid,
blood cultures, serum, cerebrospinal fluid (CSF), lung tissue,
and lymph node tissue. 
DNA from all strains was prepared with a heat lysis
method. Isolates were streaked onto trypticase soy agar con-
taining 5% sheep blood (Becton Dickinson Microbiology Sys-
tems, Cockeysville, MD) and incubated overnight at 37°C. A
single colony was transferred and dispersed into 0.22-µm cen-
trifugal filter units (Millipore, Bedford, MA) containing 200
µL 10 mM Tris-HCl (pH 8.0). The suspension was heated at
95°C for 20 min and cooled to room temperature. The filter
units were then centrifuged in a microfuge at 6,000 x g for 2
min and the filter discarded. The resulting lysate was stored at
–20°C until use. DNA from clinical specimens was extracted
with a Qiagen DNA Mini Kit per manufacturer’s instructions
(Qiagen Inc., Valencia, CA). 
MLVA typing was done as described by Keim et al. (6).
Briefly, the eight loci were amplified in four reactions: reac-
tion 1 (vrrB1, CG3, and vrrA), reaction 2 (vrrB2, pXO1-aat,
and pXO2-at), reaction 3 (vrrC1), and reaction 4 (vrrC2). In
some instances CG3 was removed from reaction 1 and ampli-
fied as a 5th reaction because of weak amplification. Each
amplicon was labeled with one of three different dyes. Prod-
ucts were separated by polyacrylamide gel electrophoresis
under denaturing conditions on an ABI 377 automated DNA
sequencer (Applied Biosystems, Foster City, CA), and allele
sizes were determined using ABI Genescan software (Applied
Biosystems).
The amplification and sequencing of pagA were performed
on 42 B. anthracis isolates and 22 clinical specimens as
described by Price et al. (8), with the following modifications.
Initially, synthetic oligonucleotide polymerase chain reaction
(PCR) primers PA-1F and PA-1R and PA-2F and PA-2R (Table
1) were used to amplify two overlapping fragments (1,119 bp
and 1,449 bp, respectively) together totaling 2,531 bp and con-
taining the pagA open reading frame (ORF) (8). Because of
inconsistent amplification with PA-2F and PA-2R and to gen-
erate a single template for sequencing, PCR amplification was
performed using primers 1566F and 4205R. In some instances,
possibly from the method of DNA purification, 1566F and
4205R did not amplify sufficiently and thus nested PCR was
performed using 1575F and 4191R. The primers used in this
study were a combination of both published primers (8) and
primers designed from the published DNA sequence of the vir-
ulence plasmid pXO1 (GenBank accession no. AF065404)
(Table 1). The pagA sequencing template was amplified by
PCR using the Expand High Fidelity PCR system (Roche,
Mannheim, Germany). Fifty-microliter PCR mixtures con-
tained 10 mM Tris-HCL (pH 8.3), 50 mM KCl, 4.0 mM
MgCl2, 0.4 mM of each forward and reverse primer, 100 µM
of each deoxynucleotide, 2.0 U of Taq  DNA polymerase
(Roche), and 2 µL of bacterial lysate. Reactions were heated at
94°C for 5 min and then cycled 35 times at 94°C for 30 s, 51°C
for 30 s, and 72°C for 1.5 min, with a final extension of 72°C
for 5 min. PCR amplicons were purified using QIAquick PCR
purification kit (Qiagen, Inc.) and the resulting purified ampli-
cons were used in the subsequent sequencing reactions.
Sequencing was performed on an Applied Biosystems
3100 genetic analyzer (Applied Biosystems) using BigDye ter-
minator cycle sequencing ready reaction mix according to
manufacturer’s instructions (Applied Biosystems). All
sequence data were analyzed with the Lasergene 99 (DNAS-
TAR, Madison, WI) software, which comprises several differ-
ent programs: DNA sequences were assembled using the
SeqMan program, and MegAlign was used to do sequence
comparisons. 
Results
By MLVA, all 135 outbreak-related B. anthracis isolates
had the following loci sizes: vrrA = 313, vrrB1 = 229, vrrB2 =
153, vrrC1 = 583, vrrC2 = 532, CG3 = 158, pXO1 = 123, and
Table 1. Primers used for amplification and sequencing of the 
pagA gene
Primer Sequence (5´ – 3´)
PA1575Fa CGA ACT GAT ACA CGT ATT TTA G
PA4191Ra AGG ATT ATG ATG ATT TAG ATT ACT
PA1566Fa  TTT ATC CGA ACT GAT ACA CGT ATT
PA4205Ra ACA AAC AAT CTC AAA GGA TTA TGA
PA-1Fa ATA TTT ATA AAA GTT CTG TTT AAA AAG CC
PA-1Ra        TAA ATC CTG CAG ATA CAC TCC CAC
PA-2Fa       ATA AGT AAA AAT ACT TCT ACA AGT AGG ACA C
PA-2Ra       GAT TTA GAT TAC TGT TTA AAA CAT ACT CTC C
PA-3         TCA TGT AAC AAT GTG GGT AGA TGA C
PA-4         CTC TAT GAG CCT CCT TAA CTA CTG AC
PA-5F        ATC CTA GTG ATC CAT TAG AAA CGA C
PA-5R        CTT CTC TAT GAG CCT CCT TAA CTA CTG
PA-5Fnest        AGT GAT CCA TTA GAA ACG AC
PA-5Rnest        TAA CTA CTG ACT CAT CCG C
PA-U2121     TAC ATT TGC TAC TTC CGC TGA TAA
PA-L3892     TGT TTT TCC ATC TTG CCG TAA
2121R TTA TCA GCG GAA GTA GCA AAT GTA
3892F  TTA CGG CAA GAT GGA AAA ACA
2557R AGC CGT GCT CCA TTT TTC AGG
3318R TGC GGT AAC ACT BTCA CTC CAG
2560F GAA AAA TGG AGC ACG GCT TCT
2924F CTT GGG CTG AAA CAA TGG GTT
aPrimers used for amplification of the pagA gene. All other primers were used for 
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pXO2 = 141, resulting in genotype 62, as described by Keim et
al. (6). In addition, the entire 2,294-bp pagA gene was
sequenced from a subset of 42 isolates: including ten patient
isolates, all four powder isolates, and 28 select environmental
isolates. All isolates had an indistinguishable sequence, PA
genotype I (Table 2). 
Before B. anthracis was detected in the mail, we subtyped
several isolates from cutaneous anthrax cases that occurred in
the 1960s and 1970s in the eastern United States to determine
if any were similar to the outbreak strain. Two isolates from
Rhode Island were MLVA genotype 71, one New Hampshire
isolate was genotype 78, while an additional New Hampshire
isolate and a Massachusetts isolate each had unique combina-
tions of alleles resulting in new genotypes. The pagA sequence
of all five New England isolates was identified as PA genotype
VI (Table 2).
State A reported isolating B. anthracis (2002017388) from
an envelope. This state was not in the vicinity of the 2001 out-
break. By MLVA, the isolate was shown to have been cured of
pXO1 and had the same genotype as the Pasteur strain, used in
laboratories as a control strain for various tests (Table 2). 
Country B sent an isolate (2002007581) that was report-
edly isolated from a letter to a private physician. MLVA identi-
fied the strain as genotype 45, which clearly distinguished it
from the strain associated with the ongoing outbreak in the
United States. In addition, four other isolates from the same
facility were assayed by MLVA (2002007648–51), resulting in
the identification of two Sterne strains, one Pasteur strain, and
one additional strain of genotype 45 (Table 2).
MLVA and pagA sequencing were performed on clinical
specimens collected from seven patients with laboratory-con-
firmed inhalational anthrax during the 2001 bioterrorism-asso-
ciated anthrax outbreak. These methods have an unproven
utility on clinical specimens, and further testing will be neces-
sary for full evaluation. A total of 28 clinical specimens were
analyzed by using MLVA, including: blood, CSF, pleural fluid,
serum, lung tissue, and lymph node tissue (Table 3). All eight
loci were detected in three specimens (two pleural fluids and
one lymph node) from patient 10. Of the eight loci examined,
vrrA was detected in all nine specimens in which any of the
MLVA loci were detected and on two occasions was the only
locus detected. The pagA gene was successfully amplified and
sequenced from 5 of 22 specimens analyzed (Table 3).
Discussion
During the 2001 anthrax investigation, molecular subtyp-
ing of B. anthracis by MLVA and pagA sequencing was
important in linking cases to each other and to contaminated
sites and in distinguishing isolates that were not related to this
event. We used two methods for the molecular subtyping of B.
anthracis: pagA sequencing and MLVA. All outbreak-associ-
ated isolates were identified as MLVA genotype 62 and PA
genotype I. To date, MLVA genotype 62 has only been associ-
ated with a few isolates from herbivores in Texas and has not
been identified in any B. anthracis strains originating in east-
ern United States or anywhere else in the world. None of the
New England isolates analyzed in this study were MLVA gen-
otype 62 or PA genotype I. All five were of PA genotype VI,
while MLVA identified two isolates as genotype 71, one as
genotype 78, and two as new genotypes. Genotype 62 is also
the genotype of the Ames strain commonly used in research
laboratories worldwide and frequently used in animal
Table 2. MLVA and pagA genotyping of Bacillus anthracis isolatesa,b
B. anthracis strain No. strains vrrA vrrB1 vrrB2 vrrC1 vrrC2 CG3 pXO1 pXO2 MLVA type PA genotype
Outbreak-associated 135 313 229 153 583 532 158 123 141 62 I
Ames 1 313 229 153 583 532 158 123 141 62 I
NH (2000032764) 1 301 229 153 538 604 158 132 139 78 VI
NH (2000032760) 1 313 229 153 538 604 158 123 139 Newe VI
RI (2000032763) 1 313 229 162 538 604 158 132 139 71 VI
RI (2000032761) 1 313 229 162 538 604 158 132 139 71 VI
MA (2000032762) 1 313 229 153 538 604 158 132 143 Newe VI
State A (2002017388) 1 313 229 162 613 604 153 – 137 Pasteurc NAd
Pasteur 1 313 229 162 613 604 153 – 137 Pasteurc NAd
Country B (2002007581) 1 313 229 162 613 532 158 129 141 45 I
Country B (2002007648) 1 313 229 162 613 532 158 129 141 45 I
Country B (2002007649) 1 313 229 162 613 604 153 – 137 Pasteurc NAd
Country B (2002007650) 1 313 229 162 583 532 158 129 _ Sternec I
Country B (2002007651) 1 313 229 162 583 532 158 129 _ Sternec I
aMLVA, multiple-locus variable-number tandem repeat analysis; pagA, protective antigen gene; PA, protective antigen; –, loci not detected; NA, not applicable.
bAllele size for each VNTR locus is shown in addition to the MLVA and PA genotypes.
cNo MLVA genotype assigned due to the lack of one of the virulence plasmids (pXO1 or pXO2).
dpagA not present in pXO1-cured strains and thus could not be assigned a PA genotype.
eNew combination of alleles resulting in a new genotype. Genotype no. to be assigned at a later date.BIOTERRORISM-RELATED ANTHRAX
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challenge studies (11–16). The sequence of pagA from the out-
break strain, PA genotype I, was also identical to that of the
Ames strain; thus, the outbreak B. anthracis strain is indistin-
guishable from the Ames strain based on the examination of
the eight MLVA loci and the pagA sequence. Recently, com-
parative genome sequencing detected only four differences
between the chromosomes of the outbreak strain (Florida iso-
late) and Ames (Porton) isolate (17). 
Molecular subtyping of isolates immediately upon their
arrival to the laboratory allowed for instant confirmation that
the cases were caused by the same strain and thus for linking
cases to environmental contamination and to the powder-con-
taining envelopes. The speed of the MLVA allowed for geno-
type identification within 8 hours of receiving the isolates. In
addition to linking the cases, molecular subtyping was invalu-
able in determining if B. anthracis, isolated from around the
Table 3. Molecular subtyping by MLVA and pagA sequencing performed on 28 clinical specimens from seven patients with inhalational anthraxa,b
Patient no.b Specimen type
Interval after anti-micro-
bial therapy (days)d MLVA loci detected pagA
Bacillus anthracis 
LRN PCRe
1 Pleural fluidc 4 All negative Negative Positive
Pleural fluidc 4 All negative Negative Positive
Bloodc 4 All negative Negative Negative
Lungc 4 All negative ND ND
Lungc 4 vrrA ND Negative
Heart bloodc 4 vrrA, vrrB1 Negative Negative
Pericardial bloodc 4 All negative Negative Positive
2 Thoracentesis fluid 4 vrrA Negative Positive
Serum 10 All negative Negative Positive
Respiratory wash 4 All negative Negative Positive
Pleural fluid 4 All negative Negative Positive
3 Blood culture 0 All negative Negative Positive
5 Blood culture 0 All negative Negative Positive
Blood culture 0 All negative Negative Positive
6 Blood culture 0 vrrA, vrrB1, vrrB2,vrrC2 Negative Positive
10 Pleural fluid 1 vrrA, vrrB1, vrrB2, vrrC1, vrrC2, CG3, 
pXO1, pXO2
Positive Positive
Pleural fluid 1 vrrA, vrrB1, vrrB2, vrrC1, vrrC2, CG3, 
pXO1, pXO2
Positive Positive
Blood 1 All negative Negative Positive
CSFc 3 All negative Negative Positive
Lungc 3 vrrA, CG3 Negative Positive
Lymph nodec 3 vrrA, vrrB1, vrrB2, vrrC1, vrrC2, CG3, 
pXO1, pXO2
Positive Positive
11 Pleural fluid 2 All negative Positive Positive
Blood 2 All negative Negative Negative
Blood culture -1 All negative ND ND
Blood culture -1 All negative ND Positive
Blood culture -1 All negative ND ND
Blood culture -1 All negative ND Positive
Lymph nodec 4 vrrA, vrrB1, vrrB2, vrrC1, vrrC2, CG3 Positive Positive
aMLVA, multiple-locus variable-number tandem repeat analysis; pagA, protective antigen gene; LRN, Laboratory Response Network; PCR, polymerase chain reaction.
bPatients 1–10 described in Jernigan et al. (19) and patient 11 in Barakat et al (20)
cSpecimens collected postmortem.
dNumber of days the specimen was collected following or before the initiation of antimicrobial therapy. Specimens collected the same day as the initiation of therapy were designated 
as day 0 but were collected before antibiotic therapy.
eResults using the Laboratory Response Network PCR assay for detection of B. anthracis during the outbreak (18).Emerging Infectious Diseases  •  Vol. 8, No. 10, October 2002 1115
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world during the same time period, were potentially related to
the ongoing outbreak in the United States. The level of dis-
crimination provided by MLVA, allowed for non-outbreak iso-
lates to be rapidly and easily distinguished.
While both MLVA and pagA sequencing are primarily
used for molecular subtyping of isolates, we were also able to
amplify the eight MLVA loci and pagA directly from a limited
number of available clinical specimens. Although this event
was not a prospective case-control study, amplification was
most successful from pleural fluid and lymph node specimens.
Similar results were demonstrated with a B. anthracis-specific
real-time PCR assay (18). Amplification of the MLVA loci and
pagA was not very successful from blood cultures even when
taken before antibiotic therapy. The lack of success with blood
cultures was not because of a complete inhibition of PCR since
the B. anthracis LRN PCR assay was positive on these speci-
mens. Of the MLVA loci, vrrA was the most readily amplified
(9 of 28). This is likely the result of a lower limit of detection
for vrrA compared to the other loci; however, limits of detec-
tion for each of the loci have not been evaluated.
For a single patient (patient 10), we were able to amplify
all eight MLVA loci and determine the genotype of the B.
anthracis strain without having the isolate itself.  In this
instance, MLVA was used directly on DNA extracted from
pleural fluid and genotype 62 was identified. B. anthracis was
not successfully cultured from that same pleural fluid sample.
The pagA gene was amplified and sequenced from the same
DNA specimen and identified as PA genotype I. MLVA and
pagA amplification were attempted on DNA extracted from
blood drawn from this patient the same day as the pleural fluid
but failed to detect any of the loci, suggesting more efficient
clearance of the bacilli from the blood or less sensitivity of
these molecular approaches on blood compared to pleural
fluid. Again, the negative result on blood was not because of
complete inhibition of PCR since the B. anthracis LRN PCR
assay on this sample was positive. At a later date, when the
Centers for Disease Control and Prevention received the iso-
late originally cultured from this patient at the local medical
facility where the patient was treated, the isolate was con-
firmed to be genotype 62. Despite the fact that B. anthracis
was not successfully cultured from any of these clinical speci-
mens taken after the initiation of antimicrobial therapy, we
were able to amplify the MLVA loci and pagA from some of
these specimens.
The entire chromosomal sequence of the B. anthracis
Ames strain (available from: URL: www.tigr.org) is now
available and has been compared to the chromosomal
sequence of the outbreak (Florida) isolate (17). While
sequencing and comparing B. anthracis genomes are not likely
to be useful for rapidly identifying isolates during an outbreak
investigation, the data generated from such comparisons may
identify new loci, which could be targets for methods such as
MLVA and can be done rapidly on large numbers of isolates
from patients, the environment, and on DNA from clinical
specimens.
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